Skip to content
Canadian orders above $200 ship free · Dispatched from Canadian stock

Buy DSIP in Canada

DSIP in Canada

Research-grade DSIP: lyophilised powder in 10 mg vials, each batch backed by HPLC identity and purity data. Stocked in Canada, for in-vitro use only.

Format
Size
$45.50$4.55/mg
Dispatched from Canadian stock

Buy more, pay less per vial

Add 2 more to save 4%

Frequently bought together

At a glance
Also known as
Delta sleep-inducing peptide · Delta-sleep-inducing peptide · Emideltide
Class
Neuropeptide (nonapeptide; receptor not identified)
Form
Lyophilised powder supplied in 10 mg vials
Sizes
10 mg
Storage, dry
−20 °C, dry and dark
Storage, mixed
2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
BAC water per size
10 mg: 2 mL
Molecular weight
About 849 g/mol (MW 849 as reported by Graf et al., 1984)

What is DSIP?

DSIP is a neuropeptide (nonapeptide; receptor not identified). Its molecular weight is about 849 g/mol (MW 849 as reported by Graf et al., 1984). The same material appears under several names in the literature, among them Delta sleep-inducing peptide, Delta-sleep-inducing peptide and Emideltide. Its recorded sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), linear. The published record is in human work. Of the 8 references below, 7 are controlled human trials. It comes as lyophilised powder in 10 mg vials, kept in Canadian stock for laboratory research. This is not a drug and is not offered for any use in a person or an animal.

What the research shows

StudyModelDose usedDurationFinding
Bes F et al.1992 · Neuropsychobiology · PMID 1299794Human, double-blind randomised matched-pairs trial in chronic insomnia (n=16)25 nmol/kg intravenous DSIP or glucose placeboGiven the afternoon before nights 3, 4 and 5 of a 5-night laboratory staySleep efficiency was higher and sleep latency shorter with DSIP, but the effects were weak and partly explained by a change in the placebo group. Subjective sleep quality did not change, and the authors concluded short-term DSIP is unlikely to be of major therapeutic benefit.
Monti JM et al.1987 · Int J Clin Pharmacol Res · PMID 3583493Human, double-blind crossover trial in chronic insomnia (n not stated in the abstract)25 nmol/kg intravenous or placebo4 nightsTotal sleep time and NREM time rose, driven by stage 2 sleep, while slow-wave and REM sleep did not change. Differences from placebo already existed at baseline, and the authors judged the improvement of little clinical significance.
Schneider-Helmert D1987 · Eur Neurol · PMID 3622582Human, placebo-controlled double-blind trial in severe chronic insomnia (n=14)Not stated in the abstract7 successive nights, plus a placebo night afterwardsNight sleep improved with the first dose and further with repeated doses, and the effect held on the first placebo night. Daytime alertness and performance increased significantly.
Schneider-Helmert D et al.1981 · Int J Clin Pharmacol Ther Toxicol · PMID 6895513Human, double-blind crossover in healthy volunteers (n=6)25 nmol/kg slow intravenous infusion, in the morningSingle infusion, sleep followed into the next nightMedian total sleep time rose 59% within 130 minutes compared with placebo, without classic sedation on EEG and behavioural tests. The next night showed shorter sleep onset and better sleep efficiency, and no side effects were observed.
Pomfrett CJ et al.2009 · Eur J Anaesthesiol · PMID 19142086Human, randomised controlled trial in women under isoflurane anaesthesia (n=24; 12 DSIP, 12 saline)Intravenous bolus of 25, 50 or 100 nmol/kgTwo doses: awake and after induction of anaesthesiaDSIP raised heart rate, lowered heart rate variability and, against the authors' hypothesis, reduced EEG delta rhythm and raised bispectral index at 25 nmol/kg, suggesting lighter anaesthesia.
Chiodera P et al.1994 · Horm Res · PMID 7698722Human, placebo-controlled trial in healthy men (n=8, plus 7 in a second arm)25 nmol/kg intravenous over 10 minutesSingle infusion before 2-hour saline or hypertonic saline, or an orthostatic testDSIP significantly lowered ACTH but did not change basal vasopressin or the vasopressin rise after hypertonic saline or standing.
Späth-Schwalbe E et al.1995 · Psychoneuroendocrinology · PMID 7777652Human, placebo-controlled studies in healthy young men (n=5 per CRH condition; n=10 meal study)Total 3 or 4 mg intravenous infusionFrom 30 minutes before to 90 minutes after CRH injection; single sessionACTH and cortisol responses to CRH and to a midday meal were almost identical with DSIP and placebo. The authors say the data do not support an inhibitory role of DSIP on ACTH and cortisol in man.
Giusti M et al.1993 · Psychoneuroendocrinology · PMID 8475226Human, controlled study in healthy women (n=8)25 micrograms/kg intravenous over 30 minutes (or 1 hour in the circadian arm)Single infusionsDSIP did not change basal growth hormone or prolactin, their circadian rhythm, or their response to arginine.

What these studies don't show: Trials do exist, though their reach is narrower than it first looks. Participants are screened, many of the endpoints are proxies, and most trials finish early. The results apply to the setting studied and no further. An HPLC trace reports what is present, and that is a different matter from efficacy.

Every study links to its PubMed record. See all DSIP studies in the research library →

DSIP price in Canada: 10mg vial

Buy DSIP in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.

SizePricePer mg
10 mg$45.50$4.55/mg

Starter kit

Is DSIP available in Canada?

DSIP is not listed in the Drug Product Database as an authorized product. It has undergone no safety, efficacy or quality review by Health Canada. In-vitro research is what Borealis Peptides keeps it for; it is supplied for use in no living subject. How Health Canada treats research peptides →

Side effects reported in studies

Every statement here is linked to the study that recorded it. Any tolerability finding below is quoted straight from the study that reported it. Human work on this scale does not establish a safety profile.

DSIP FAQ

What is DSIP?

Both suppliers and the literature treat DSIP as a neuropeptide (nonapeptide; receptor not identified). Its published record is in human work. Borealis Peptides provides it as lyophilised powder in 10 mg vials for in-vitro laboratory research. It holds no medicine authorization and is not for use in any living subject. The studies behind it are listed on this page with the model each one used and what the authors reported.

Where can I buy DSIP in Canada?

Borealis Peptides dispatches DSIP from stock held in Canada to research and business addresses across the country. The format is 10 mg vials. HPLC testing covers each batch, and the certificate identifies the batch in your particular vial. We accept orders for laboratory research only.

Is DSIP legal in Canada?

DSIP is not listed in the Drug Product Database as an authorized product. It has undergone no safety, efficacy or quality review by Health Canada. Borealis Peptides keeps it on hand for in-vitro research and sells it for use in no living subject. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we read it as setting out what the material is supplied for, well short of permission. Establishing lawful use in your own setting is up to you.

How much DSIP should I use?

Borealis Peptides provides no dosing, protocols or reconstitution volumes, and will not supply them on request. In laboratory work the amount follows from the study design, which a supplier is in no position to set. The figures on this page are what particular published studies used in their own models: a record of what was done, not a recommendation.

What human evidence is there for DSIP?

Of the 8 cited studies, 7 are controlled trials in people and the rest are animal or cell work. Each row lists its model, the amount used and the authors' reported outcome, so every study can be weighed on its own terms instead of through a summary.

How long does DSIP keep?

Unopened, keep it at −20 °C in the dark. After reconstitution, 2–8 °C. Ambient transit does the dry powder no harm, and it should be refrigerated once received. Light and repeated warming cause more damage than the journey does. Testing runs batch by batch, so the certificate matches the vial rather than the product line.

How is the purity of DSIP confirmed?

Identity and purity are verified by HPLC for each batch, not once per product. The certificate names the batch it covers, and that batch number sits on the vial, so a result can be traced back to the exact material behind it. Ask with your order number and we will send it.

How does DSIP compare with Epitalon and Selank?

They are distinct compounds with distinct published records, and this site does not rank them. Epitalon and Selank have 8 cited studies and 8 cited studies on their page against 8 here. The comparison worth making is to read both tables alongside the models each one used.

Why is DSIP named in a Health Canada advisory?

Because it was one of the peptides seized from sellers offering unauthorized injectable products online. That advisory deals with material sold for people to inject without authorization. Borealis Peptides stocks research material for in-vitro laboratory work and sells nothing for injection or for any use in a person, precisely the separation the advisory is concerned with.

Compare with